Yuemeng Wu

Background: Abrocitinib has shown significant efficacy and safety in clinical trials for moderate‐to‐severe atopic dermatitis (AD), but long‐term real‐world data are scarce. Objective: To assess the long‐term efficacy, predictors of response, and safety profiles associated with abrocitinib treatment in a real‐world setting. Methods: This prospective study enrolled 147 moderate‐to‐severe AD patients, and physician‐ and patient‐reported outcomes were evaluated at multiple time points. Results: Abrocitinib rapidly reduced Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), Itch Numeric Rating Scale (Itch‐NRS), and body surface area (BSA) from Week 4 throughout Week 52, with 83.1% and 53.2% of patients achieving EASI‐75 and EASI‐90, respectively, at Week 52. Improvement was less pronounced in the head and neck compared to the trunk and limbs. Shorter disease duration (<   84 months) and the absence of allergic comorbidities predicted better long‐term response. Patients achieving EASI‐75 or EASI‐90 by Week 4 were more likely to maintain control at Week 52. Drug survival was 72.7% at Week 52. Adverse events (AEs) occurred in 61.9% of patients, with acneiform eruptions (19.7%) and gastrointestinal symptoms (17.7%) being most common within Week 12. After 12 weeks, hypercholesterolemia, abnormal liver function, and infections increased. Conclusion: Abrocitinib showed promising long‐term efficacy and safety in Chinese patients with moderate‐to‐severe AD, while consistent lab monitoring is required. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2200063195

Background/Objective: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by diverse clinical manifestations. However, variations in its clinical presentations across different ages, genders, anatomical sites, and seasons remain incompletely understood. The objective was to explore the clinical heterogeneities of AD using data from the Chinese non-selective registration system. Methods: A prospective analysis was conducted on 3829 AD patients enrolled in the Chinese Non-selective Registry for AD (CNRAD) at hospital settings from 2020 to 2022. Demographic profiles; distribution, type, and severity of the skin lesion; laboratory findings; allergic comorbidities; family history; and exacerbating factors were analyzed. Results: The male-to-female ratio was 0.92 among adolescent and adult AD patients but increased to 2.11 in elderly AD patients, highlighting an age-dependent gender difference in AD prevalence. Age groups displayed distinct anatomical preferences for lesion distribution, with reduced involvement of the cubital and popliteal fossae in adult and elderly patients. Based on skin lesion characteristics, ten clinical subtypes of AD were proposed. Elderly AD patients exhibited higher severity, compared to adolescence and adult AD patients, with male patients being more severe than females. Elderly AD patients showed a lower proportion of extrinsic type, compared to childhood AD patients. Seasonal change emerged as the most important factor triggering AD flares. Conclusions: This study provides new insights into the heterogeneities of AD clinical manifestations in the Chinese population, demonstrating their significant dependence on temporal factors, including age and season.

Background and Objectives: To compare the efficacy and safety of fractional 1064 nm Nd:YAG picosecond laser and nonablative fractional 1565 nm laser in the treatment of enlarged pores.Study Design/Materials and Methods: Twenty patients received five monthly treatments at months 0, 1, 2, 3, and 4 and were followed up at months 5, 6, and 7. All patients were treated by fractional 1064 nm Nd:YAG picosecond laser (FxPico) on the left face, and nonablative fractional 1565 nm laser (ResurFx) on the right face as a control.Results: For the 19 patients who completed the study, both sides demonstrated significant improvement on pore counts (p < 0.01), while there was no significant difference between the two sides 3 months after the final treatment (p = 0.092). Excellence rate on the FxPico side (57.9%) was significantly better than the ResurFx side (36.8%) (p < 0.05). Sebum secretion and porphyrin value significantly decreased on both sides after five treatments and there was a higher reduction of sebum level on the ResurFx side. There was no difference between the two therapies in terms of overall satisfaction. Pain of treatment for the ResurFx side (average VAS 4.45 ± 1.60) is significantly higher than that for the FxPico side (average visual analog scale [VAS] 1.48 ± 1.36) (p < 0.001). Erythema, edema, and petechiae were common adverse effects and were mild to moderate. There was significantly higher incidence of hyperpigmentation for the ResurFx side (52.6%) compared with that for the FxPico side (5.3%) (p < 0.001).Conclusion: Fractional 1064 nm Nd:YAG picosecond laser and nonablative fractional 1565 nm laser both are effective, efficient, and safe treatment regimens for enlarged pores, while fractional 1064 nm Nd:YAG picosecond laser has better clinical response with less treatment pain, shorter recovery period and much lower induction of hyperpigmentation.

Background: Dupilumab, an antibody against interleukin‐4 receptor α, has demonstrated elegant efficacy and safety profiles in patients with moderate‐to‐severe atopic dermatitis (AD). However, the efficacy of dupilumab varies among AD patients, and compared with the Caucasian population, the data of dupilumab for Asian people, especially Chinese AD patients, is very limited.Objective: To investigate the efficacy and safety of dupilumab for AD in a real‐world Chinese single‐centre prospective cohort.Methods: We enrolled 138 moderate‐to‐severe AD patients receiving dupilumab treatment at Huashan Hospital, Shanghai, China in this 16‐week, single‐centre, prospective, open‐label study. The patients were evaluated at baseline, 2, 4, 8 and 16 weeks after first dupilumab administration for multiple physician‐ and patient‐reported outcome measures. Blood eosinophil counts and total serum IgE were measured.Results: There were early and sustained improvement in all the efficacy measures evaluated after dupilumab administration. 64.5% AD patients achieved an improvement of ≥75% in the Eczema Area and Severity Index from baseline, and 60.9% patients achieved the Investigator's Global Assessment 0/1 (or a reduction of ≥2 points from baseline) at week 16. The trunk demonstrated the most significantly decreased efficacy score [median decreased 96.24% (interquartile range, 89.04 to 100%)] compared with other body sites. Female (adjusted OR: 2.12, 95% confidence interval: 0.79–5.74) and body mass index (BMI) 60 (0.57; 0.10–3.28) predicted poor response. Adverse events were reported by 34.1% patients, and facial erythema (13%) and ocular symptoms (10.9%) were the most common.Conclusions: Dupilumab demonstrated favourable efficacy and well‐tolerated safety in Chinese AD patients in real‐world practice.